Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:5–21.
   PubMedGoogle Scholar
• Zaninoni A, Imperiali FG, Pasquini C, et al. Cytokine modulation of nuclear factor-kappa B activity in B-chronic lymphocytic leukemia. Exp Hematol 2003;31:185–190.
   PubMed Web of Science ®Google Scholar
• Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383–389.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Montesano R, Clerici G, et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol 2002;71:177–183.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Capalbo S, Agostinelli RM, et al.; GIMEMA Chronic Lymphocytic Leukemia Group. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006;91:1689–1692.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230–239.
   PubMed Web of Science ®Google Scholar
• Lad DP, Varma S, Varma N, et al. Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma 2013;54:1012–1029.
   PubMed Web of Science ®Google Scholar
• Visco C, Novella E, Peotta E, et al. Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica 2010;95:1230–1232.
   PubMed Web of Science ®Google Scholar
• Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control 2012; 19:18–25.
   Google Scholar
• Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003;15:5–11.
   PubMed Web of Science ®Google Scholar
• Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004;430:257–263.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499–511.
   PubMed Web of Science ®Google Scholar
• Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006;36:810–816.
   PubMed Web of Science ®Google Scholar
• Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol 2013;10:103–106.
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006;20:286–295.
   PubMed Web of Science ®Google Scholar
• Grandjenette C, Kennel A, Faure GC, et al. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007;92:1279–1281.
   PubMed Web of Science ®Google Scholar
• Muzio M, Scielzo C, Bertilaccio MT, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:507–516.
   PubMed Web of Science ®Google Scholar
• Mills KHG. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011;11:807–822.
   PubMed Web of Science ®Google Scholar
• Marta M, Andersson A, Isaksson M, et al. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008;38:565–575.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Cramer P, Hallek M. Hematological cancer in 2011: new therapeutic targets and treatment strategies. Nat Rev Clin Oncol 2011;8:38–47.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198–206.
   PubMed Web of Science ®Google Scholar
• Rose NR, Bona C. Defining criteria for autoimmune diseases. Immunol Today 1993;14:426–430.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford: Blackwell Science; 2002.
   Google Scholar
• Clayton D, Hills M. Statistical models in epidemiology. Oxford: Oxford University Press; 1993.
   Google Scholar
• StataCorp. Stata statistical software: release 12. College Station, TX: StataCorp LP; 2011.
   Google Scholar
• Rozková D, Novotná L, Pytlík R, et al. Toll-like receptors on B-CLL cells:expression and functional consequences of their stimulation. Int J Cancer 2010;126:1132–1143.
   PubMed Web of Science ®Google Scholar
• Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia:distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 2011;96:1644–1652.
   PubMed Web of Science ®Google Scholar
• Jarnicki AG, Conroy H, Brereton C, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008;180:3797–3806.
   PubMed Web of Science ®Google Scholar
• den Haan JM, Kraal G, Bevan MJ. Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4 + T cells that suppress the CD8+T cell response. J Immunol 2007;178:5429–5433.
   PubMed Web of Science ®Google Scholar
• Nickerson KM, Christensen SR, Cullen JL, et al. TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J Immunol 2013;190:1447–1456.
   PubMed Web of Science ®Google Scholar
• Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008;20:332–338.
   PubMed Web of Science ®Google Scholar
• Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005;17:230–236.
   PubMedGoogle Scholar
• Visco C, Maura F, Tuana G, et al. Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. Clin Cancer Res 2012;18:1870–1878.
   PubMed Web of Science ®Google Scholar
• Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012;119:4467–4475.
   PubMed Web of Science ®Google Scholar
• Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med 2012;18:1281–1291.
   PubMed Web of Science ®Google Scholar